Fexofenadine 120mg with Montelukast 10mg Tablets are a multi-API pharmaceutical combination-tablet dosage form with the two APIs blended within a single solid dose. Multi-API pharmaceutical tableting involves selecting compatible ingredients, evaluating particle properties, developing a blending process, understanding the tableting process, and defining finished-product specifications. Because the active ingredients are present at different dosage levels within the final product, the product-development process needs to focus on achieving good distribution of each active within the tablet. This combination-tablet formulation can be contained within the Portfolio formulation file and be used in a PCD Pharma Franchise company, with appropriate manufacturing controls and documentation.
The API combination involves a defining target strength of 120mg and 10mg respectively. The pre formulation of the two APIs requires assessment of their properties as a common powder base.
Each API raw material can be characterized for particle size, bulk density, flow rate, moisture content, compressibility, and other relevant bulk property information. These properties can influence the process selection for blending and compression.
A suitable excipient formula can be devised according to the approved formulation. Disintegrants, binders, lubricants, glidants, diluents, and other ingredients can be selected based on the intended purpose.
Pre formulation can include studies of Fexofenadine, Montelukast, and excipient compatibility. The materials can be mixed under prescribed conditions of time and temperature, and physical or chemical interactions can be monitored.
The physical properties of each component can be compared with those of the blend. Final tablet specifications may be determined with respect to tablets' weight, size, tablet ability, hardness, disintegration, and dissolution.
The tablet manufacturing process involves measuring the two APIs according to the approved dosage formula and confirming the accuracy of weight and composition on-line before beginning tablet production.
Since the two active ingredients are present in differing amounts, practices such as premixing, controlled batching, and geometric dilution may be useful to maintain a homogenous distribution of each within the final blend.
Bulk materials can be sieved or milled so as to provide a suitable particulate size distribution with good flow properties and minimal tendency for segregation.
The order of addition, mixing time, blend agitation, and transfer procedures may be controlled through predetermined formulation protocol. Blended material can be sampled from multiple locations to confirm homogeneous distribution according to the sampling plan.
Extra care may be taken when transitioning between blending and compression stages, as differences in the properties of each active-material type can encourage segregation.
Depending on their physical properties, the blend can be directly tableted, or a granulation process may be employed. When granulation is used, added binders, granulation, drying, and sizing stages are included according to a formulation schedule. The final moisture level should be specified.
Tablet compression process factors such as compression load, press-head speed, die fill rate, and turret rotation speed can be controlled within established limits. In-process monitoring may include tablet weight, thickness, hardness, friability, and appearance.
The formulation may be tableted as an uncoated or film-coated tablet, with final coating attributes optimized according to the approved product design. The coating process requires attention to spray rate, pan rotation rate, pan design, temperature and air quality.
Final compression parameters are optimized to balance the appearance and strength of the tablet with its ability to meet the desired disintegration and dissolution characteristics.
Finished-product testing includes the evaluation of both individual active pharmaceutical agents, as well as general tablet characteristics. Assay procedures can be employed in batch-testing for each active agent using validated analytical methodology.
Content uniformity test is particularly important to a combination dosage form to demonstrate the consistent distribution of both API components of the fill. Repeat testing of samples according to the sampling plan can be employed to confirm this.
Dissolution testing of both active agents can be achieved using appropriate analytical procedures. These procedures can be able to identify any interference from excipients and any potential degrading species.
Other quality standards for the finished-tablet include disintegration, friability, hardness, weight variation, moisture content, and visual characteristics. Any relevant tests for the film coating can also be performed.
Analytical instruments require qualification, with validation or verification of analytical procedures according to national standards. Proper data recording is essential with documentation of all raw-data and calculations.
Sample-stability testing over an established shelf life can demonstrate the form's ability to retain its specifications. Assays of both active ingredients and dissolution behavior may be used to inform the stability profile.
Physical appearance, moisture content, and the stability of the active ingredients can also be monitored throughout stability-testing. Packaging packages can be selected in light of the compound's specified stability profile.
The compatibility of the tablet with the selected packaging system should be evaluated with respect to any potential interactions and impacts on appearance. The packaging integrity should be confirmed through a system integrity test.
Following stability testing, the product can be finished with appropriate packaging. The compatibility of the finished tablets with the packaging material may be evaluated, with the packaging references kept in the batch record.
The finished-labeling and batching code should include all approved product details and strengthen in the form of the approved formulation.
The tableted combination product can be contained within a varied pharmaceutical portfolio with the formulation development, manufacturing controls, and product specifications adequately defined. For portfolio-management businesses working within the PCD Pharma Franchise sector, clear product information should be applied across all material, packaging, and label media.
A formulation file may include all raw-material standards, approved sources, formulation ratio, master manufacturing instructions, in-process control points, analytical procedures, finished-product specifications, packaging specifications, and stability test data.
The coordination between the two active ingredients should focus on controlled dispensing, mixing, and blending procedures, with sampling and analytical evaluation used to confirm uniformity in both active ingredients within the blend.
All aspects of production should be covered by thorough controls and recorded for accuracy, including raw-material receipt and storage, dispensing, mixing, granulation (where applicable), tableting, coating (where applicable), quality control, and batch review.
For portfolio management, product-design interfaces such as labels, catalogs, and digital listings should incorporate the product-name, strength, and key information of the composition.
Developing a controlled combination-API tableting product such as Fexofenadine 120mg with Montelukast 10mg Tablets involves managing compatibility and characterization of both individual ingredients. Accurate dispensing, blending, processing, and quality-control protocols must be implemented to ensure a consistently high-quality and repeatable product for inclusion within a portfolio or PCD Pharma Franchise network.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech